Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EPS (Basic) (2018 - 2025)

Historic EPS (Basic) for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$0.26.

  • Whitehawk Therapeutics' EPS (Basic) rose 4347.83% to -$0.26 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.14, marking a year-over-year increase of 10614.04%. This contributed to the annual value of -$2.36 for FY2024, which is 342.98% up from last year.
  • Per Whitehawk Therapeutics' latest filing, its EPS (Basic) stood at -$0.26 for Q3 2025, which was up 4347.83% from -$0.76 recorded in Q2 2025.
  • Whitehawk Therapeutics' 5-year EPS (Basic) high stood at $6.96 for Q4 2021, and its period low was -$9.17 during Q3 2021.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.6 (2021), whereas its average is -$0.61.
  • Per our database at Business Quant, Whitehawk Therapeutics' EPS (Basic) crashed by 64552.85% in 2021 and then skyrocketed by 37058.82% in 2025.
  • Over the past 5 years, Whitehawk Therapeutics' EPS (Basic) (Quarter) stood at $6.96 in 2021, then crashed by 106.9% to -$0.48 in 2022, then dropped by 25.0% to -$0.6 in 2023, then decreased by 12.67% to -$0.68 in 2024, then surged by 61.54% to -$0.26 in 2025.
  • Its EPS (Basic) stands at -$0.26 for Q3 2025, versus -$0.76 for Q2 2025 and $1.84 for Q1 2025.